drugset / Trial / NCT07392736
A Phase I/IIa Study of AL8326 Combined With Toripalimab in the Treatment of Advanced Solid Tumors.
NaSingle-groupOpen-labelScreening
Summary
This trial is an open, non-randomized, phase I/IIa clinical trial, which will evaluate the preliminary effectiveness and safety of AL8326 tablets in patients with advanced solid tumors
Timeline
- Start
- 2021-10-26
- Primary completion
- 2029-11-07
- Completion
- 2029-11-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AL8326 | Unknown | 10 mg | Oral |
| Background | Toripalimab | Monoclonal antibody | 240 mg | — |